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Abstract 
A series of p-cymene ruthenium(II) complexes with imidazol-2-yl phosphines as PN ligands 
was prepared. Depending on the number of imidazolyl substituents in the ligands Ph3-nP(im)n 
{1–3: n = 1–3, im = imidazol-2-yl (a), 1-methylimidazol-2-yl (b)} different coordination 
modes were observed: P, 2N,N or 3N,N,N. The complexes were tested for their 
cytotoxicity in different cancer cell lines. Most of the compounds were found to be non-toxic; 
The compounds [(p-cymene)Ru(1a)Cl2] (4a) shows cytotoxicity towards A2780sens and 
Hct116 cells in the µM range but not in H4IIE cells. The cytotoxicity is decreased upon 
introduction of a methyl group as [(p-cymene)Ru(1b)Cl2] (4b) shows only modest toxicities 
in the cell lines investigated. The P compound [(p-cymene)Ru(2a)Cl2] (5a) shows selective 
toxicity in H4IIE cells after 72 hours whereas the 2N,N compound [(p-
cymene)Ru(2a)Cl]OTf (5a’) showed no toxicity in the cell lines investigated which again. 
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1. Introduction 
Since the authorization of cisplatin in 1978, the interest in and development of metal-based 
drugs prospers consistently. Still, cisplatin, cis-[Pt(NH3)2Cl2], and its analogs, especially 
oxaliplatin and carboplatin, are basic chemotherapeutics in combination therapy.[1-3] The 
therapeutic effect of cisplatin is based on DNA platination which triggers apoptosis.[4] The 
major draw-back for a successful chemotherapy by platinum-based drugs is acquired 
resistance towards the applied drug during the course of therapy.[5] In order to circumvent 
those resistance mechanisms drugs, which address alternative cellular targets have to be 
developed. [6-8] 
The most promising metallodrugs besides cisplatin analogues are ruthenium-based 
drugs.[9,10,10-13] Compounds of Ru(II) and Ru(III) are able to overcome cisplatin resistance. 
Their cytotoxicity and antimetastatic properties are combined with low overall toxicity.[9,14-17] 
Trans-[RuCl4(dmso)(Im)]ImH (NAMI-A, where Im = imidazole) has completed phase I 
clinical trials.[18] Interestingly, NAMI-A is more active against metastases than against 
primary tumours.[19] Half-sandwich Ru(II) arene complexes of the type [(η6-
arene)Ru(YZ)(X)], where YZ is a bidentate chelating ligand and X is a good leaving group, 
show promising in vitro and in vivo anticancer activity.[16] These compounds coordinate to 
guanine N7 of DNA, which can be complemented by intercalative binding of an extended 
arene, as well as specific hydrogen-bonding interactions.[20,21] For example, increasing the 
size of the coordinated arene is accompanied by an increase in activity in human ovarian 
cancer cell lines[16] and the nature of the chelating ligand YZ and leaving group X seems 
influence their kinetics and even can change their nucleobase selectivity.[22] The RAPTA 
family of organometallic Ru(II) compounds contain the water-soluble phosphine ligand 
phosphaadamantane (pta) or derivatives thereof. Usually these compounds exhibit moderate 
in vitro activity, and some compounds show no activity in healthy cells up to millimolar 
concentrations. The pta compounds show little activity against primary tumours in vivo, 
although they exhibit some capacity to reduce lung metastases derived from a mammary 
carcinoma xenograft grown in mice.[23] The cytotoxicity of [Ru(η6-p-cymene)Cl2(pta)], in 
EAC cells is thought to be mediated by mitochondrial and Jun-N (amino)-terminal kinase 
(JNK)–p53 pathways.[24] For all Ru(II) compounds it is believed that in vivo, analogous to 
cisplatin, aquation of the chlorido complex is largely suppressed in intracellular fluids (with 
chloride concentrations are about 100 mM), whereas in the cell nucleus with a much lower 
chloride concentration (ca. 4 mM) the active aqua species forms.[25,26] Although their 
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mechanism of action is still largely unknown, there is some evidence that RAPTA compounds 
work on molecular targets other than DNA,[27-29] implying a biochemical mode of action 
profoundly different from classical platinum anticancer drugs. 
We are currently examining the use of imidazole-based PN ligands in biomedical 
applications[30-32] as well as in catalysis[33,34]. Here we present coordination chemistry of these 
PN ligands towards (η6-cymene)Ru(II) and basic cytotoxicity studies in different cancer cell 
lines. 
2. Experimental Section 
The ligands Ph3-nP(im)n {1–3: n = 1–3, im = imidazol-2-yl (a), 1-methylimidazol-2-yl (b)} 
and [(cym)Ru(P-1b)Cl2] (4b) were prepared according published procedures.[32,34-37] All 
reactions were carried out in Schlenk tubes under an atmosphere of dry nitrogen using 
anhydrous solvents purified according to standard procedures. All chemicals were purchased 
from commercial sources and used as received. 1H and 31P NMR spectra were recorded on a 
Bruker DRX 200 and Bruker DRX 500 spectrometer. The 1H spectra were calibrated against 
the residual proton signal of the solvent as an internal reference (methanol-d4: H = 3.31 ppm; 
D2O: H = 4.79 ppm, CDCl3: H = 7.26 ppm) while the 31P{1H} NMR spectra were referenced 
to external 85% H3PO4. The MALDI mass spectra were recorded on a Bruker Ultraflex 
MALDI-TOF mass spectrometer. The elemental composition of the compounds was 
determined with a PerkinElmer Analysator 2400 at the Institut fur Pharmazeutische und 
Medizinische Chemie, Heinrich-Heine-Universitat Dusseldorf. 
2.1 Synthesis of (cym)Ru-complexes 
2.1.1 [(cym)Ru(P-1a)Cl2] (4a) 
Ligand 1a (83 mg, 0.33 mmol) and [Ru(cym)Cl2]2 (100 mg, 0.16 mmol) were dissolved in dry 
CH2Cl2 (15 mL) and stirred for 24 hours. The dark red solution was concentrated to 5 mL and 
Et2O was added.  The precipitate was collected and dissolved in thf, filtered and again 
precipitated upon addition of n-hexane. The red solid was filtered off and dried in vacuo. 
Yield: 52 mg (28 %). 1H-NMR (200 MHz, methanol-d4): δ = 0.97 (d, J = 7.0 Hz, 6H), 1.83 (s, 
3H), 2.42 (sept., J = 7.0 Hz, 1H), 5.42 (m, 4H), 7.10 (d, J = 1.2 Hz, 2H), 7.72 (m, 10H). 
31P{1H}-NMR (81 MHz, methanol-d4): δ = 22 (s). EI-MS (CH3OH): m/z (%) = 558 (40) 
[M]+, 523 (28) [M-Cl]+, 486 (100) [M-2Cl]+, 389 (27) [M-C10H14]+, 352 (45) [M-C10H14-Cl]+. 
C25H27Cl2N2PRu (558.45): calc. C 53.77, H 4.87, N 5.02; found C 53.44, H 4.98, N 4.77.  
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2.1.2 [(cym)Ru(P-2a)Cl2] (5a) 
Ligand 2a (50 mg, 0.21 mmol) and [Ru(cym)Cl2]2 (63 mg, 0.1 mmol) were dissolved in dry 
CH3CN (25 mL) and stirred for 24 hours. The dark red solution was concentrated to 5 mL. 
The red precipitate was filtered off, washed with Et2O and dried in vacuo. Yield: 27 mg (24 
%). 1H-NMR (200MHz, CDCl3): δ = 0.97 (d, J = 7.0 Hz, 6H), 1.76 (s, 3H), 2.47 (sept., J = 
7.0 Hz, 1H), 5.83 (m, 4H), 7.26 (d, J = 1.2 Hz, 4H), 7.39 (m, 5H). 31P{1H}-NMR (81 MHz, 
CDCl3): δ = –1 (s). ESI-MS (CH3OH): m/z (%) = 513.4 (43) [M-Cl]+, 477.4 (100) [M-2Cl]+. 
C22H25Cl2N4PRu·H2O (566.43): calc. C 46.65, H 4.80, N 9.89; found C 47.08, H 5.20, N 9.65. 
2.1.3. [(cym)Ru(2N,N-2a)Cl]OTf (5a’) 
 [Ru(cym)Cl2]2 (101 mg, 0.16 mmol) and AgOTf (85 mg, 0.33 mmol) were dissolved in dry 
CH3CN (15 mL) and refluxed for 1 hour. Precipitated AgCl was filtered off and the red 
filtrate was added to a suspension of 2a (80 mg, 0.33 mmol) in dry CH3CN (10 mL). The 
reaction mixture was refluxed for one hour and stirred for 24 h at ambient temperature. The 
resulting yellow solution was concentrated to ca. 3 mL and Et2O was added. The mixture was 
kept at –18 °C. The yellow precipitate was filtered off, washed with Et2O and dried in vacuo. 
Yield: 154 mg (70 %). 1H-NMR (200 MHz, methanol-d4): δ = 1.31 (d, J = 6.9 Hz, 6H), 2.04 
(s, 3H), 2.91 (sept., J = 6.9 Hz, 1H), 5.73 (m, 4H), 7.30 (d, J = 1.47 Hz, 2H), 7.46 (d, J = 1.5 
Hz, 2H), 7.68 (m, 5H). 31P{1H}-NMR (81 MHz, methanol-d4): δ = –22 (s). ESI-MS 
(CH3OH): m/z (%) = 493.5 (100) [M+O]+, 477.5 (15) [M]+, C23H25ClF3N4O3PRuS·½ H2O 
(671.03): calc. C 41.16, H 3.91, N 8.49; found C 41.15, H 3.42, N 8.43. 
2.1.4. [(cym)Ru(2N,N-2b)Cl]Cl (5b) 
[Ru(cym)Cl2]2 (100 mg, 0.16 mmol) and 2b (118.9 mg, 0.33 mmol) were dissolved in dry 
CH3CN (15 mL) and stirred for 24 hours. The orange solution was concentrated to 5 ml and 
Et2O was added. The resulting solid was filtered off, washed with Et2O and dried in vacuo. 
Yield: 158 mg (84 %). 1H-NMR (200 MHz, CDCl3): δ = 1.25 (d, J = 7.0 Hz, 6H), 1.67 (s, 
3H), 2.66 (sept., J = 7.0 Hz, 1H), 4.20 (s, 6H), 4.94 (m, 4H), 7.15 (d, J = 1.4 Hz, 2H), 7.56 
(m, 5H), 7.83 (d, J = 1.4 Hz, 2H). 31P{1H}-NMR (81 MHz, CDCl3): δ = –60 (s). ESI-MS 
(CH3OH): m/z (%) = 541.4 (76) [M]+, 505.5 (35) [M-Cl]+, 407.3 (100) [M-C10H14]+, 371.4 
(37) [M-C10H14-Cl]+. C24H29Cl2N4PRu·2 H2O (612.50): calc. C 47.1, H 5.4, N 9.1; found C 
47.1, H 5.3, N 9.2. 
2.1.5. [(cym)Ru(3N,N,N-3a)]Cl2 (6a) 
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[Ru(cym)Cl2]2 (50 mg, 0.082 mmol) and 3a (38.2 mg, 0.16 mmol) were dissolved in dry 
CH3CN (30 mL) and refluxed for 2 hours. The yellow precipitate was collected by filtration, 
washed with a small amount of CH3CN and dried in vacuo. Yield: 21 mg (24 %). 1H-NMR 
(200 MHz, methanol-d4): δ = 1.20 (d, J = 6.7 Hz, 6H), 2.45 (s, 3H), 3.24 (sept., J = 6.7 Hz, 
1H), 6.28 (m, 4H), 7.47 (dd, J = 1.6 Hz, J = 2.94 Hz, 3H), 8.23 (d, J = 1.6 Hz, 3H). 31P{1H}-
NMR (81 MHz, methanol-d4): δ = –103 (s). ESI-MS (CH3OH): m/z (%) = 467.3 (100) [M]+, 
234 (58) [M-3a]+. C19H23Cl2N6PRu·5/2 H2O (583.38): calc. C 39.1, H 4.8, N 14.4; found C 
39.3, H 4.5, N 14.1.  
2.1.6. [(cym)Ru(3N,N,N-3b)]Cl2 (6b) 
[Ru(cym)Cl2]2 (100 mg, 0.16 mmol) and 3b (91 mg, 0.33 mmol) were dissolved in dry 
CH3CN (25 mL) and refluxed for 1.5 hours. The yellow precipitate was collected, washed 
with a small amount of CH3CN and dried in vacuo. Yield: 26 mg (18 %). 1H-NMR (200 
MHz, methanol-d4): δ = 1.23 (d, J = 6.7 Hz, 6H), 2.45 (s, 3H), 3.23 (sept., J = 6.7 Hz, 1H), 
4.03 (s, 9H), 6.29 (m, 4H), 7.55 (dd, J = 1.6 Hz, J = 4.0 Hz, 3H), 8.21 (d, J = 1.6 Hz, 3H). 
31P{1H}-NMR (81 MHz, methanol-d4): δ = –116 (s). ESI-MS (CH3OH): m/z (%) = 509 (100) 
[M-Cl]+, 461 (29) [M-C4N2H6+Cl]+. C22H29Cl2N6PRu (580.46): calc. C 45.5, H 5.0, N 14.5; 
found C 45.2, H 4.9, N 14.1. 
2.1.7. [(cym)Ru(2N,N-en)Cl]Cl (7) 
[Ru(cym)Cl2]2 (100 mg, 0.16 mmol) was solved in dry CH3CN (25 mL). A yellow solid 
precipitated upon addition of an excess of ethylendiammine (en). The reaction mixture was 
stirred for 20 minutes to complete the reaction. The solid was filtered off, washed with dry 
CH3CN and dried in vacuo. Yield: 99 mg (84 %). 1H-NMR (200 MHz, methanol-d4): δ = 1.27 
(d, J = 7.0 Hz, 6H), 2.43 (s, 3H), 2.70 (m, br, 4H), 2.81 (sept., J = 7.0 Hz, 1H), 5.81 (m, 4H). 
ESI-MS (CH3OH): m/z (%) = 295 (100) [M-Cl]+, 235 (34) [M-Cl-en]+. 
2.2. Distribution coefficients (logD) 
The n-octanol–water distribution coefficients of the compounds were determined using a 
shake-flask method. PBS buffered bi-distilled water (100 mL, phosphate buffer, c(PO43–) = 10 
mM, c(NaCl) = 0.15 M, pH adjusted to 7.4 with HCl) and n-octanol (100 mL) were shaken 
together using a laboratory shaker (Perkin Elmer), for 72 h to allow saturation of both phases. 
1 mg of each compound was mixed in 1 mL of aqueous and organic phase, respectively for 10 
min using a laboratory vortexer. The resultant emulsion was centrifuged (3000 g, 5 min) to 
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separate the phases. The concentrations of the compounds in the organic and aqueous phases 
were then determined using UV absorbance spectroscopy (230 nm). LogDpH was defined as 
the logarithm of the ratio of the concentrations of the complex in the organic and aqueous 
phases logD = log([compound(org)]/[compound(aq)]), the value reported is the mean of three 
separate determinations. 
2.3. DNA Binding Studies 
The UV/Vis kinetic studies and thermal denaturation temperature Tm determinations for 1:5 
complex/ DNA mixtures [DNA concentration = M(base pairs)] were performed in a 10 mM 
phosphate buffer at pH = 7.4. Melting curves were recorded at 2 °C steps for the wavelength 
260 nm with an Analytik Jena SPECORD 100 spectrometer and a thermostat. ∆Tm values 
were calculated by determining the midpoints of melting curves. The experimental ∆Tm 
values are estimated to be accurate within ±1 °C. Concentrations of calf thymus (ct) DNA 
were determined spectrophotometrically using the molar extinction coefficient ε260 = 13200 
M–1 cm–1.[38] 
2.4.  Cell culture 
Hct116 human colon carcinoma and H4IIE rat hepatoma cells were grown in Dulbecco´s 
modified Eagle´s medium (DMEM, GIBCO; Germany), A2780 human ovarian carcinoma 
cells were grown in RPMI cell culture medium; all media contained 10 % fetal calf serum 
(PAA Laboratories; Austria), penicillin (100 U / mL) and streptomycin (100 µg / mL) at 5 % 
CO2 and 37 °C.  
2.5. Determination of cytotoxicity 
The effect of the compounds on cell viability was determined using the MTT assay.[39] Cells 
were plated on 96-multiwell plates (H4IIE, Hct116 cells: 15.000 / well, A2780 cells: 35.000 / 
well), allowed to attach for 24 h and then treated with different concentrations of the 
substances for indicated time points. In all experiments compounds were dissolved in dmso. 
The dmso concentration was equal at all compound concentrations analyzed. The highest 
dmso concentration used was 1%; no toxic effect was detected at this concentration. After 
treatment medium was changed and cells were incubated for 30 min under cell culture 
conditions with 1 mg / mL MTT. Then the cells were lysed with 100 % dmso. The 
concentration of reduced MTT as a marker for cell viability was measured photometrically 
(560 nm) using a Wallace Victor2 1420 multilabel counter (Perkin-Elmer). 
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2.6.  Statistical analysis 
All data were analyzed using one-way analysis of variance, followed by Bonferroni or Dunnet 
post hoc analysis to determine statistical significance. P values < 0.05 were considered 
statistically significant. The analysis was performed with GraphpadPrism 5.0c. 
2.7. Crystallography 
Crystals of compounds 5a and 5a’. CH2Cl2 suitable for X-ray study were selected by means of 
a polarisation microscope and investigated with a STOE Imaging Plate Diffraction System, 
using graphite monochromatized MoK radiation ( = 0.71073 Å). Unit cell parameters were 
determined by least-squares refinements on the positions of 8000 reflections. Space group 
type no. 14 was uniquely determined for both compounds. Corrections for Lorentz and 
polarization effects were applied. The structures were solved by direct methods (SHELXS-
86)[40] and subsequent F-syntheses. Approximate positions of all the hydrogen atoms were 
found in different stages of converging refinements by full-matrix least-squares calculations 
on F2.[40] Anisotropic displacement parameters were refined for all atoms heavier than 
hydrogen. With idealised bonds lengths and angles assumed for all the CH, CH2 and CH3 
groups, the riding model was applied for the corresponding H atoms and their isotropic 
displacement parameters were constrained to 120%, 120% and 150% of the equivalent 
isotropic displacement parameters of the parent carbon atoms, respectively. In addition, the H 
atoms of the CH3 groups were allowed to rotate around the neighboring C-C bonds. 
Crystallographic data of 5b2CH3CN½H2O were collected at 183(2) K on an Oxford 
Diffraction Xcalibur system with a Ruby detector using Mo Kα radiation (λ = 0.7107 Å) that 
was graphite-monochromated. Suitable crystals were covered with oil (Infineum V8512, 
formerly known as Paratone N), mounted on top of a glass fibre and immediately transferred 
to the diffractometer. The program suite CrysAlisPro was used for data collection, multi-scan 
absorption correction and data reduction.[41] The structure was solved with direct methods 
using SIR97[42] and was refined by full-matrix least-squares methods on F2 with SHELXL-
97.[40] The structure was checked for higher symmetry with help of the program Platon.[43] 
CCDC entries 867104 (5a), 867105 (5a’.CH2Cl2) and 861637 (5b2CH3CN½H2O) contain 
the supplementary crystallographic data (excluding structure factors) for this paper. These 
data can be obtained free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
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3. Results and Discussion 
3.1. Syntheses and characterisation 
We prepared the (cym)Ru complexes (cym = p-cymene) by reaction of [{(cym)RuCl2}2] and 
the corresponding ligands 1a,b – 3a,b in acetonitrile (Scheme 1). The corresponding 
complexes precipitated from solution or were obtained in analytically pure form after addition 
of Et2O.  
Ru Cl
ClCl
Ru
Cl Ru Cl
NCCH3
Cl
Ru Cl
Ph2P
Cl
RN
N
Ru
NNN
N
RNR
N
RP
Ru
ClNN
N
H
N
HP
Ph
Ru
ClNN
N NP
Ph
Ru Cl
PhP
Cl
N
H
N
2
2Cl Cl OTf + AgOTf
– AgCl
CH3CN
+ 1a 
or 1b
+ 2a
+ 2b
+ 3a
or 3b
+ 2a
+ AgOTf
– AgCl
5a
4a (R = H)
4b (R = CH3)
5a'5b6a (R = H)
6b (R = CH3)  
Scheme 1. Reaction of [{(cym)RuCl2}2] in acetonitrile with ligands 1–3 yields compounds 4–
6.  
All compounds exhibit sharp singlet resonances in their 31P{1H} NMR spectra (Table 1). The 
analytical data of complex 4a are nearly identical to the one of 1b which has been previously 
described by Caballero et al. Complexes 6a and 6b show one set of signals for the ligands in 
the 1H NMR (methanol-d4), indicating local C3v symmetry. Additionally, their 31P{1H} NMR 
spectra show the typical coordination shift to about –110 ppm which is indicative for the 
3N,N,N coordination mode in complexes of tris(imidazolyl)phosphine ligands.[44-46] 
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Table 1. 31P{1H} resonances (C) of the (cym)Ru complexes 4a,b – 6a,b and the 
corresponding coordination shifts ( = C – L, ain methanol-d4, bin CDCl3). 
Compound (31P) / ppm (31P) / ppm 
4a 22a + 45 
4b 8b + 35 
5a 1b + 46 
5a’ –22a + 23 
5b –60b – 15 
6a –103a – 43 
6b –116a – 44 
 
The ligands 1a/b in complexes 4a and 4b show the P coordination mode and the ligands 
3a/b in complexes 6a and 6b show the 3N,N,N mode. The coordination modes found in the 
isolated complexes of ligands 2a and 2b are more complex. Initially, the reaction of 
[{(cym)RuCl2}2] with the PN phosphine ligands proceeds via a P coordinated species. The 
course of the reactions was monitored by 31P NMR and even during formation of 6a and 6b 
signals for a transient species, tentatively assigned to P species (see Fig. ESI1), was 
observed. All attempts to ‘trap’ P bound ligands 3a/b, e.g. by reaction of these ligands with 
[(cym)Ru(en)Cl] (7), finally resulted in formation of compounds 6a and 6b, respectively.  
When ligands 2a and 2b were used, P coordination can compete with the chelating 2N,N 
binding mode. Those coordination modes were found in compounds 5a’ and 5b (both 2N,N) 
and 5a (P) which were unambiguously assigned by their single crystal structures (see 
below). As mentioned previously, P coordination leads to a classical coordination shift of 
the 31P resonance towards lower field whereas chelating 2N,N (or 3N,N,N in 6a,b) results in 
a shift towards higher field (Table 1). The reaction of 2b with [{(cym)RuCl2}2] yields 5b, 
where only 2N,N coordination of 2b is observed. The related ligand 2a can adopt both 
coordination P and 2N,N modes depending on the chloride concentration in solution. The 
reaction of stoichiometric amounts of [{(cym)RuCl2}2] and 2a gives a mixture of 
[(cym)Ru(2P-2a)Cl2] (5a) and [(cym)Ru(2N,N-2a)Cl]+ and unreacted ligand (Fig. 1). 
Addition of one equivalent of Ag(O3SCF3) to that reaction mixture quantitatively yields 5a’. 
This reaction is not reversible as 5a’ is persistent even in the presence of high chloride 
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concentration (up to >100 fold) as was shown by 31P NMR spectroscopy. Therefore small 
electronic changes in the ligand system, like introduction of electron donating methyl groups, 
can favour one binding mode over the other. This might be of importance as this might alter 
their cytotoxicity profiles, e.g. in the presence of other coordinating ligands as chloride.  
5a
 
Fig. 1. 31P{1H}-NMR spectrum of the reaction mixture of [{(cym)RuCl2}2] and 2a in dmso-
d6. The ligand 2a and complexes [(cym)Ru(2P-2a)Cl2] (5a) and [(cym)Ru(2N,N-2a)Cl]+ 
with P and 2N,N coordination mode show resonances at –50, 3 and 23 ppm. 
 
3.2. Solid-state structures 
The solid-state structures of compounds 5a’, 5a and 5b were determined by single crystal 
analysis and crystallographic data is summarized in Table 2. Compounds 5a’ and 5a 
crystallised in the monoclinic space group P21/c. Compound 5b crystallised as solvate 
5b.3CH3CN. ½H2O in the monoclinic space group P21/n. The ruthenium atom in all structures 
is in octahedral coordination sphere with the η6-cymene ligand occupying one face of the 
octahedron. In 5a the other three positions are occupied by two chlorido ligands and κP-
bound 2a (Fig. 2). In 5a’ and 5b the κ2N,N-coordination mode of the PNN ligands 2a and 2b 
is found (Fig. 3 and Fig. 4). The ruthenium atom is coordinated by 2a/b in the chelating κ2N,N 
mode and a chlorido ligand. The other chloride or CF3SO3– acts as counter-ion to the complex 
cations, respectively. The metric parameters found in 5a and 5a’/5b are within the range 
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found for other compounds [(cym)Ru(PR3)Cl2][31,35,47-49] and complexes [(cym)Ru(N–N)Cl]+ 
with diammino ligands[31,50,51]. 
In the solid-state structures of 5a and 5b the phenyl substituents of the corresponding ligand 
2a/b and the p-cymene ligand at the ruthenium atom adopt cis (5b) and trans positions (5a’) 
(Scheme 2). The compounds 5a and 5a’, bearing ligand 2a with NH functionalities, show 
hydrogen bonding in their solid-state structures. 
In the solid state of 5a’ intermolecular hydrogen bonds are formed between N2H1…O1(triflate) 
and N4H2…Cl1 thus forming one-dimensional arrays. Also in the solid state of 5a the 
intermolecular hydrogen bonds N3H2…Cl2 result in formation of one-dimensional arrays. 
Additionally a weak bifurcated intramolecular hydrogen bond between N1H1 and Cl1 and 
Cl2 is found. 
 
Fig. 2. Molecular structure of 5a. Non-acidic hydrogen atoms are omitted for clarity. The 
displacement ellipsoids are shown on a 50% level. Selected bond lengths [Å] and angles [°]: 
Ru1-P1 2.3477(7), Ru1-Cl1 2.4173(7), Ru1-Cl2 2.4165(8), P1-Ru1-Cl1 87.41(3), P1-Ru1-
Cl2 86.60(3), Cl1-Ru1-Cl2 87.39(3).  
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Fig. 3. Molecular structure of 5a’.CH2Cl2. Uncoordinated counter ion, non-acidic hydrogen 
atoms and solvent molecule are omitted for clarity. The displacement ellipsoids are shown on 
a 50% level. Selected bond lengths [Å] and angles [°]: Ru1-N1 2.096(4), Ru1-N3 2.087(3), 
Ru1-Cl1 2.4006(15), N1-Ru1-N3 84.28(14), N1-Ru1-Cl1 85.21(12), N3-Ru1-Cl1 85.84(11).  
 
 
Fig. 4. Molecular structure of 5b.2CH3CN. ½H2O. Uncoordinated counter ion, hydrogen atoms 
and solvent molecules are omitted for clarity. The displacement ellipsoids are shown on a 
  14
50% level. Selected bond lengths [Å] and angles [°]: Ru1-N1 2.090(2), Ru1-N3 2.097(2), 
Ru1-Cl1 2.3897(7), N1-Ru1-N3 2.3897(7), N1-Ru1-Cl1 85.21(6) N3-Ru1-Cl1 84.61(6). 
Ru
Cl
N
N
P
NR
NR
iPr
Ph
Ru
Cl
N
N
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Scheme 2. The trans and cis isomers found in the solid-state structures of 5a’ (R= H) and 5b 
(R = CH3). 
Table 2. Crystallographic data for compounds 5a, 5a’ and 5b.2CH3CN. ½H2O. 
Compound  5a 5a’.CH2Cl2 5b.2CH3CN. ½H2O   
Empirical formula  C22H25Cl2N4PRu C24H27Cl3F3N4O3PRuS C28H36Cl2N6O0.5PRu
Formula weight  548.40 746.96 667.57 
Temperature / K 291(2) 291(2) 183(2) 
Wavelength / Å 0.71073 0.71073  0.71073 
Crystal system  Monoclinic Monoclinic Monoclinic 
Space group  P 21/c P 21/c P 21/n 
Unit cell dimensions    
a / Å 17.2041(9) 14.985(2) 10.98070(16) 
b / Å 9.7578(8) 7.7408(8) 12.8114(2) 
c / Å 14.1705(7) 26.642(4) 23.9097(4) 
α / ° 90 90 90 
β / ° 103.729(6) 98.273(18) 93.5635(14) 
γ / ° 90 90 90 
Volume / Å3 2310.9(3) 3058.2(7)  3357.07(9) 
Z 4 4 4 
Density (calculated) / 
Mg/m3 
1.576 1.622  1.321 
Absorption coefficient / 
mm–1 
0.996 0.947  0.701 
F(000) 1112 1504 1372 
Crystal size / mm3 0.3 x 0.3 x 0.3 0.2 x 0.2 x 0.2  0.24 x 0.18 x 0.11 
Theta range for data 
collection 
2.42 to 24.99° 1.91 to 25.92° 2.63 to 33.14° 
Index ranges -20<=h<=20, 
-11<=k<=11,  
-16<=l<=16 
-18<=h<=18,  
-9<=k<=9,  
-32<=l<=32 
-16<=h<=14,  
-19<=k<=13,  
-36<=l<=36 
Reflections collected 29702 35580 31289 
Independent reflections 4013 [R(int) = 
0.0438] 
5920 [R(int) = 0.0977] 12777 [R(int) = 
0.0355] 
Completeness to theta  98.3 % to 24.99° 99.4 % to 25.92° 99.9 % to 33.14° 
Absorption correction None None Semi-empirical 
from equivalents 
Refinement method Full-matrix least-
squares on F2 
Full-matrix least-
squares on F2 
Full-matrix least-
squares on F2 
Data / restraints / 4013 / 0 / 279 5920 / 0 / 364 12777 / 7 / 380 
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parameters 
Goodness-of-fit on F2 1.045 0.932 0.967 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0283, wR2 
= 0.0665 
R1 = 0.0373, wR2 = 
0.0603 
R1 = 0.0456, wR2 = 
0.1232 
R indices (all data) R1 = 0.0365, wR2 
= 0.0681 
R1 = 0.1079, wR2 = 
0.0653 
R1 = 0.0790, wR2 = 
0.1324 
Largest diff. peak and 
hole / e.Å–3 
0.626 and -0.323 0.569 and -0.650  1.027 and -0.703 
 
3.3. Biological studies 
Biological studies were performed on compounds 4a,b, 5a,b and 5a’ as well as 6a and 6b. 
The n-octanol–water distribution coefficients of compounds 4a,b, 5a,b and 5a’ were 
determined as logD7.4 values using phosphate buffered saline (PBS).  The logD7.4 value 
decreases within the series 4a > 4b > 5a’ > 5a > 5b (Table 3). The introduction of additional 
imidazolyl groups in the κP complexes increases the water-solubility of the compounds as 
does the introduction of charge in complexes 5a/b. Surprisingly, the complexes having N-
methyl groups in the PN ligands are more water soluble than their NH-congeners. 
A decrease in thermal denaturation temperature of 7 °C in the presence of 4a, 4b and 5a’, 
respectively and of 4 °C in the presence 5b was recorded for calf-thymus DNA (ctDNA) at a 
molar ratio of r = 0.2 where [DNA] is given in M(base pairs) (Table 3 and Supporting 
Information). Interestingly, the melting curve in the presence of 5a shows two stages 
corresponding to decreases in thermal denaturation temperature of 8 and 28 °C respectively. 
This might reflect a rearrangement of the coordination mode of the ligand in the complex as 
discussed before. 
Table 3. Experimental n-octanol/water (PBS buffer pH 7.4) distribution coefficients (logD7.4) 
and DNA melting temperatures (ΔTm) at a ratio of metal complex / DNA (in base pairs) of 1 / 
5. The ∆Tm values are estimated to be accurate within ±1 °C. 
Compound logD7.4 Tm / °C ΔTm / °C 
4a 1.25 ± 0.03 66 7 
4b 1.14 ± 0.05 66 7 
5a 0.14 ± 0.03 45, 65 28, 8 
5a’ –0.33 ± 0.02 66 7 
5b –0.68 ± 0.01 69 4 
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The cytotoxicity of the compound was determined towards three different cell lines using the 
MTT assay method. For comparison, the compound [(cym)Ru(en)Cl]Cl (7) was also 
introduced in the cell line studies (Table 4 and Fig. 5). Cell lines used were Hct116 human 
colon carcinoma, H4IIE rat hepatoma and A2780 human ovarian carcinoma cells (cisplatin 
sensitive). The cytotoxicity values for these compounds fall in the range commonly observed 
for various Ru(arene)-type complexes. [31,52,53] 
As expected, the complexes coordinatively saturated 6a and 6b are not cytotoxic at 
concentrations up to 100 µM after 24, 48 and 72 hours of incubation, respectively (Table 4). 
Compounds 5a’ and 5b containing 2N,N bonded ligands show no toxicity in the cell lines 
used. The steric repulsion of the imidazolyl groups in 5b may hinder coordination to DNA 
bases. Additionally, the NH groups in 5a’ point away from a possible binding site due to the 
ligand geometry. In complexes [(arene)Ru(en’)X] with ethylene diammine derivatives (en’) it 
has been shown that NH functionalities in the en’ ligand are essential for efficient DNA 
binding.[20,54,55] 
The compounds [(p-cymene)Ru(1a)Cl2] (4a) shows cytotoxicity towards A2780sens and 
Hct116 cells in the µM range but not in H4IIE cells. The cytotoxicity is decreased upon 
introduction of a methyl group as [(p-cymene)Ru(1b)Cl2] (4b) shows only modest toxicities 
in the cell lines investigated. In general 4a is more cytotoxic then 4b. As mentioned above, 
free NH functions as in [(arene)Ru(en’)X] should favour DNA binding. This is not a valid 
explanation here, as the melting temperatures for 4a and 4b are essentially the same.  
Table 4. Cell viability tests after 24 and 72 hours of incubation, IC50 values given in µM (n.d. 
not determined). 
Cell line Incubation 
time 
4a 4b 5a 5a’ 5b 6a 6b 
A2780sens 24 h 83 >100 >100 >100 >100 n.d. n.d. 
 72 h 38 95 >100 >100 >100 n.d. n.d. 
Hct116 24 h 66 >100 >100 >100 >100 >100 >100 
 72 h 58 >100 n.d. n.d. n.d. >100 >100 
H4IIE 24 h >100 >100 >100 >100 >100 >100 >100 
 72 h >100 >100 54 >100 >100 >100 >100 
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Although 5a and 4a both have the P binding mode and therefore resemble RAPTA-type 
[(arene)RuCl2(pta)] complexes, 5a is almost non-toxic in the cell lines investigated within 24 
of incubation. After 72 and 96 hours of incubation a selective toxicity of 5a towards H4IIE 
cells is found (Table 4 and Fig. 6). Reason for the decreased toxicity of compound 5a to 4a 
might be the hydrophobicity. The selective toxicity of 5a in H4IIE cells might be an effect of 
5a in the cell cycle leading to delayed toxic effects. In addition it is well known, that RAPT-
type complexes not only act as DNA binders. The poor correlation found here could also 
point towards a different mechanism, where proteins are favoured targets for the compounds. 
For corresponding complexes this has been shown by the groups of Messori and Davey. [29,56] 
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Fig. 5. Cytotoxic effects 5a, 5a´, 5b and 7 in H4IIE and A2780 cells. H4IIE rat hepatoma and 
A2780 human ovarian carcinoma cells were incubated with 5a, 5a´, 5b or 7 (100 µM) for 
72 h, then MTT reduction as a marker of cell viability was measured (absorbance at 560 nm). 
Results are expressed as viable cells in percent of control value ± SD. (n = 3, *:p < 0,05 vs. 
corresponding DMSO control). 
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Fig. 6. Cytotoxic effects of 5a in H4IIE. H4IIE rat hepatoma cells were incubated with 
different concentrations of 5a for 48, 72 and 96 h, then MTT reduction as a marker of cell 
viability was measured (absorbance at 560 nm). Results are expressed as viable cells in 
percent of control value ± SD. (n = 3, *:p < 0,05 vs. corresponding DMSO control). 
 
4. Conclusion 
We prepared a series of ruthenium(II) arene complexes with ambidentate PN ligands. All 
compounds displaying a chelating 2N,N or 3N,N,N coordination mode show no cytotoxicity 
towards the used Hct116, H4IIE and A2780 cell lines. The most lipophilic complex 4a show 
the highest cytotoxicity within the series of compounds, with IC50 values in the micromolar 
range. Complex 5a, in which ligand 2a is bound in the P mode, shows a selective 
cytotoxicity towards H4IIE cells after 72 hours. In contrast complex 5a’, in which ligand 2a is 
bound in the 2N,N mode, shows no cytotoxic effects in the cell lines investigated.  
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Fig ESI1. 31P{1H}-NMR spectra taken from the reaction mixture of [{(cym)RuCl2}2] and 3b 
in MeCN. 
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Fig. ESI2. Excerpts of the 1H und 31P{1H} NMR spectra of [(cym)Ru(κ2N,N-2b)Cl]Cl (5b) in 
CDCl3. 
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Fig. ESI3.  DNA melting curves in the presence of complexes 4a-5b. Thermal denaturation 
temperatures (TM) were determined using the Origin software package (Boltzmann 
sigmoidal curve fitting).  
 
